If QPX9003 makes it through Phase II and III clinical trials and onto the market, it will be the first new lipopeptide antibiotic that targets Gram-negative bacteria in over 60 years.
QPX9003, a new antibiotic for Gram-negative bacteria, has achieved success in a Phase I clinical trial.